I was diagnosed with thyroid cancer in Nov., 1999. Surgery and radioactive iodine followed. In Dec., 2006, I found a lump in my neck that turned cancerous. Shortly thereafter, it was found to have metastasized throughout my body and to be untreatable and inoperable. I started a clinical trial with Sutent (sunitinib) since Apr., 2007.
In Nov., 2013, the tumors began growing again and I was removed from the Sutent Clinical Trial. I started a clinical trial taking of CEDIRANIB on 04/09/14.
Telomerase reverse-transcriptase promoter mutations could be a major
indicator of tumor aggressiveness in differentiated thyroid carcinomas.
In a retrospective observational study, they were associated with
distant metastases, poor response to treatment and outcomes.
The study included 647 tumors and tumor-like
lesions in 469 patients with follicular cell-derived thyroid carcinomas
treated and followed in five university hospitals.
The telomerase reverse-transcriptase (TERT)
promoter mutations were observed in 7.5% of papillary carcinomas (PTC),
17.1% of follicular carcinomas (FTC), 29% of poorly differentiated
carcinomas (DTC) and 33.3% of anaplastic thyroid carcinomas, according to data.
“The detection of such mutations appears to be, per se, a promising prognostic indicator in DTC and PTC,” researchers wrote.
In the group with DTC, TERT-mutated tumors were associated with older age (P<.001) and larger tumors (P=.002). In addition, TERT promoter mutations were significantly associated with distant metastases (P<.001) and higher stage (P<.001), researchers wrote.
Patients with DTC and TERT promoter mutations tended to be exposed to more radioiodine treatments (P=.009) with a greater cumulative dose (P=.004), and administered more treatment modalities (P=.001), researchers wrote.
“The most important added value of the present study is that we found evidence showing that patients with TERT mutated tumors had
decreased survival when compared with patients with tumors harboring
wild-type TERT and, moreover, that this holds true for the whole DTC
series, as well as for PTC and FTC independently,” researchers wrote.
At 7.8 years follow-up, researchers found that patients with TERT-mutated DTC were more likely to display persistent disease (P=.001);
TERT promoter mutations were significantly associated with
disease-specific mortality among patients with follicular cell-derived
thyroid carcinomas (P<.001), DTC (P<.001), PTC (P=.001), and FTC (P<.001).
After adjustments for age at diagnosis and sex, researchers wrote
that the HR was 10.35 (95% CI, 2.01-53.24) in DTC and 23.81 (95% CI,
1.36-415.76) in PTC.
“Our findings suggest a link between telomerase activity and metastatic capacity may exist,” researchers wrote. Disclosure: The researchers report no relevant financial disclosures.